The phase 3 randomized clinical trial involves a clonidine micropellet, which is half the size of a grain of rice and placed in the lower back to combat sciatica pain for up to one year.
Interventional pain company Sollis Therapeutics developed the micropellet as a non-opioid alternative to treat chronic pain caused by sciatica. More than 5 million people in the U.S. suffer from sciatica, which is one of the most common causes of back and leg pain.
“Innovative technologies that act directly at a target location like this micropellet are crucial to reducing the need for systemic medications and opioids for chronic pain,” said neurosurgeon Ali Rezai, MD.
More articles on spine:
Dr. Joshua Rovner among spine surgeons performing robotic surgery: 3 details
Top 10 ‘Spine Review’ articles: Nov. 19-23
What spine surgeons are most thankful for in 2018
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
